###begin article-title 0
###xml 10 11 10 11 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Increased d-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study
###end article-title 0
###begin p 1
###xml 43 45 43 45 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 1049 1050 1049 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1075 1076 1075 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1403 1405 1403 1405 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 636 644 <span type="species:ncbi:9606">patients</span>
###xml 900 908 <span type="species:ncbi:9606">patients</span>
###xml 994 1002 <span type="species:ncbi:9606">patients</span>
###xml 1322 1330 <span type="species:ncbi:9606">patients</span>
An important risk gene in schizophrenia is d-amino acid oxidase (DAAO). To establish if expression of DAAO is altered in cortical, hippocampal or thalamic regions of schizophrenia patients, we measured gene expression of DAAO in a post-mortem study of elderly patients with schizophrenia and non-affected controls in both hemispheres differentiating between gray and white matter. We compared cerebral post-mortem samples (granular frontal cortex BA9, middle frontal cortex BA46, superior temporal cortex BA22, entorhinal cortex BA28, sensoric cortex BA1-3, hippocampus (CA4), mediodorsal nucleus of the thalamus) from 10 schizophrenia patients to 13 normal subjects investigating gene expression of DAAO in the gray and white matter of both hemispheres of the above-mentioned brain regions by in situ-hybridization. We found increased expression of DAAO-mRNA in the hippocampal CA4 of schizophrenic patients. Compared to the control group, both hemispheres of the hippocampus of schizophrenic patients showed an increased expression of 46% (right, P = 0.013) and 54% (left, P = 0.019), respectively. None of the other regions examined showed statistically significant differences in DAAO expression. This post-mortem study demonstrated increased gene expression of DAAO in the left and right hippocampus of schizophrenia patients. This increased expression could be responsible for a decrease in local d-serine levels leading to a NMDA-receptor hypofunction that is hypothesized to play a major role in the pathophysiology of schizophrenia. However, our study group was small and results should be verified using larger samples.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 67 71 67 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">1987</xref>
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2002</xref>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">1999</xref>
###xml 413 415 413 415 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2002</xref>
###xml 482 486 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2004</xref>
###xml 715 716 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 724 726 724 726 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 855 859 855 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">1996</xref>
###xml 862 864 862 864 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 968 972 968 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">1995</xref>
###xml 1106 1110 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2006</xref>
###xml 1128 1132 1128 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2007</xref>
###xml 1312 1316 1312 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2006</xref>
###xml 1363 1365 1363 1365 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 1400 1402 1400 1402 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 1416 1418 1416 1418 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 1451 1453 1451 1453 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 1494 1498 1494 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2002</xref>
###xml 1512 1514 1512 1514 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 1541 1542 1541 1542 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1586 1590 1586 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">1999</xref>
###xml 1646 1648 1646 1648 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 1676 1680 1676 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1994</xref>
###xml 1696 1700 1696 1700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">1995</xref>
Schizophrenia is a complex neurodevelopmental disorder (Weinberger 1987; Lewis and Levitt 2002), in which susceptibility genes are assumed to play a specific role in the pathophysiology of the disease via abnormal synaptic connectivity (Harrison 1999). Genome wide scanning and mapping of regions associated with risk for schizophrenia led to the detection of several hypothetical susceptibility genes, including d-amino acid oxidase (DAAO) (Chumakov et al. 2002; Schumacher et al. 2004) in addition to a number of established risk genes. These genes encode proteins involved in processes beginning with brain development to the maintenance of glutamatergic transmission in the adult brain. DAAO is involved in the N-methyl-d-aspartate receptor (NMDAR) hypofunction that is hypothesized to play a major role in the pathophysiology of schizophrenia (Coyle 1996). d-Serine, an allosteric activator of the NMDA-type glutamate receptor (NMDAR) in the brain (Schell et al. 1995), is degraded by DAAO. Accordingly, increased DAAO levels might lead to NMDAR dysfunction via decreased serine levels (Kapoor et al. 2006; Bendikov et al. 2007). DAAO itself is a peroxisomal homodimeric flavoenzyme showing the characteristics of the dehydrogenase-oxidase class of flavoproteins with a low kinetic efficiency (Molla et al. 2006). DAAO catalyzes the oxidative deamination of d-amino acids, with the exception of d-aspartate and d-glutamate, which are oxidized by d-aspartate oxidase (DASPO) (Sacchi et al. 2002). Endogenous d-serine is synthesized from l-serine by serine racemase (Wolosker et al. 1999), and is degraded by DAAO, which specifically oxidizes d-amino acids (Horiike et al. 1994; Schell et al. 1995).
###end p 4
###begin p 5
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2002</xref>
###xml 104 108 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2004</xref>
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2004</xref>
###xml 148 152 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2007</xref>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">2007</xref>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2005</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2007</xref>
###xml 656 658 656 658 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 1081 1085 1081 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2006</xref>
###xml 1391 1395 1391 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2006</xref>
###xml 1554 1558 1554 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2006</xref>
###xml 1768 1772 1768 1772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2008</xref>
The DAAO risk gene has been shown to be associated with schizophrenia (Chumakov et al. 2002; Liu et al. 2004; Schumacher et al. 2004; Corvin et al. 2007; Wood et al. 2007). While the influence of a single risk gene is considered rather small, the coherent influence of multiple susceptibility genes is said to contribute significantly to the risk of developing schizophrenia in either an epistatic or a polygenic mode (Harrison and Weinberger 2005). Li and He (2007) performed a meta-analysis combining all case-control and family-based association studies published until October 2005 that involve 16 polymorphisms, including those assessing the genes of d-amino acid oxidase (DAAO) activator (DAOA or G72; located on chromosome 13q32-34) and DAAO (located on chromosome 12q24). Although previous studies have reported strong associations in allelic, genotypic or haplotypic analyses, the results of the presented meta-analysis provided only weak evidence for an association between DAOA/DAAO genes and schizophrenia. Another meta-analysis on DAOA by Detera-Wadleigh and McMahon (2006) presented highly significant evidence of an association between nucleotide variations in the DAOA/DAAO region and schizophrenia. It is interesting to note that the alleles and haplotypes were not identical across the studies-some of them were located 50 kb telomeric of DAOA (Detera-Wadleigh and McMahon 2006). However, there were no real genotypes available, which prevented comparison of haplotype frequencies. Association tests with DAAO, made by Goldberg et al. (2006) were consistently non-significant. They performed two family-based association studies of various single nucleotide polymorphisms in the gene for DAAO. The latest meta-analysis was carried out by Shi et al. (2008) and combined 18 associating studies conducted before April 2007 involving 15 single nucleotide polymorphisms. Of these, two showed an association with schizophrenia in Asians while one was found to be associated with the disorder in Europeans.
###end p 5
###begin p 6
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2004</xref>
###xml 348 352 348 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">1995</xref>
###xml 372 376 372 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1999</xref>
###xml 392 396 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2001</xref>
While no single marker showed evidence of an overall association with bipolar disorder (Schumacher et al. 2004) several authors hypothesized that DAOA and DAAO might also contribute to bipolar affective disorder, because linkage findings in the chromosomal regions of DAOA and DAAO had similarly been discovered for bipolar disorder (Dawson et al. 1995; Jones and Tarrant 1999; Kelsoe et al. 2001). Additionally, the psychopathological characteristics shared by both schizophrenia and bipolar disorder, leading to the assumption of a commonly shared etiology, also underscore this hypothesis.
###end p 6
###begin p 7
###xml 642 646 642 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2005</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 180 185 <span type="species:ncbi:9606">human</span>
###xml 519 527 <span type="species:ncbi:9606">patients</span>
###xml 1161 1169 <span type="species:ncbi:9606">patients</span>
###xml 1314 1322 <span type="species:ncbi:9606">patients</span>
In order to emphasize the linkage between DAAO and schizophrenia in a severely affected subpopulation of schizophrenia patients, we investigated gene expression of DAAO in several human brain regions [granular frontal cortex (BA9), middle frontal cortex (BA46), superior temporal cortex (BA22), the entorhinal cortex (BA28), sensoric cortex (BA1-3), the hippocampus (CA4) and the mediodorsal nucleus of the thalamus] by in situ-hybridization. We determined mRNA levels in the right and left hemisphere of schizophrenia patients versus healthy subjects, respectively. So far, it is known that DAAO-mRNA is localized in astrocytes (Yang et al. 2005). Due to the cell specific expression of DAAO in varying cell populations, we chose to analyze gray and white matter in BA9, BA46, BA22, BA28 and BA1-3 separately. We hypothesized a differential expression of DAAO in key regions of schizophrenia pathophysiology, namely the hippocampus CA4. Schizophrenia is not a uniform disease. Instead, it could best be characterized as a syndrome with the different courses of the disease being associated with different neurobiological backgrounds, i.e. first episode versus patients with a chronic course of the disease. Accordingly, we tried to measure DAAO gene expression in the brains of a severely affected subgroup whose patients were thought to have had a similar course of schizophrenia.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human post-mortem tissue
###end title 9
###begin p 10
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 130 131 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 655 659 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">1994</xref>
###xml 964 968 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">1989</xref>
###xml 977 978 977 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1388 1395 1388 1395 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1395 1497 1395 1497 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="11">Characteristics of post-mortem samples from patients with schizophrenia and normal comparison subjects</p>
###xml 1395 1497 1395 1497 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="11">Characteristics of post-mortem samples from patients with schizophrenia and normal comparison subjects</p></caption>
###xml 1497 1511 1497 1511 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Characteristic</th>
###xml 1552 1553 1552 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1511 1559 1511 1559 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tissue from patients with schizophrenia (<italic>n</italic>&#160;=&#160;10)</th>
###xml 1596 1597 1596 1597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1559 1603 1559 1603 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tissue from normal patient subjects (<italic>n</italic>&#160;=&#160;13)</th>
###xml 1603 1603 1603 1603 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1603 1603 1603 1603 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1497 1603 1497 1603 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Characteristic</th><th align="left">Tissue from patients with schizophrenia (<italic>n</italic>&#160;=&#160;10)</th><th align="left">Tissue from normal patient subjects (<italic>n</italic>&#160;=&#160;13)</th><th align="left"/><th align="left"/></tr>
###xml 1497 1603 1497 1603 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Characteristic</th><th align="left">Tissue from patients with schizophrenia (<italic>n</italic>&#160;=&#160;10)</th><th align="left">Tissue from normal patient subjects (<italic>n</italic>&#160;=&#160;13)</th><th align="left"/><th align="left"/></tr></thead>
###xml 1620 1621 1620 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1603 1622 1603 1622 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Subjects gender (<italic>N</italic>)</td>
###xml 1622 1624 1622 1624 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1624 1626 1624 1626 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 1626 1626 1626 1626 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1626 1626 1626 1626 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1603 1626 1603 1626 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Subjects gender (<italic>N</italic>)</td><td char="." align="char">10</td><td char="." align="char">13</td><td align="left"/><td align="left"/></tr>
###xml 1626 1630 1626 1630 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 1630 1631 1630 1631 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1631 1633 1631 1633 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 1633 1633 1633 1633 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1633 1633 1633 1633 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1626 1633 1626 1633 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Male</td><td char="." align="char">5</td><td char="." align="char">11</td><td align="left"/><td align="left"/></tr>
###xml 1633 1639 1633 1639 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Female</td>
###xml 1639 1640 1639 1640 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1640 1641 1640 1641 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1641 1641 1641 1641 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1641 1641 1641 1641 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1633 1641 1633 1641 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Female</td><td char="." align="char">5</td><td char="." align="char">2</td><td align="left"/><td align="left"/></tr>
###xml 1603 1641 1603 1641 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Subjects gender (<italic>N</italic>)</td><td char="." align="char">10</td><td char="." align="char">13</td><td align="left"/><td align="left"/></tr><tr><td align="left">Male</td><td char="." align="char">5</td><td char="." align="char">11</td><td align="left"/><td align="left"/></tr><tr><td align="left">Female</td><td char="." align="char">5</td><td char="." align="char">2</td><td align="left"/><td align="left"/></tr></tbody>
###xml 1497 1641 1497 1641 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Tissue from patients with schizophrenia (<italic>n</italic>&#160;=&#160;10)</th><th align="left">Tissue from normal patient subjects (<italic>n</italic>&#160;=&#160;13)</th><th align="left"/><th align="left"/></tr></thead><tbody><tr><td align="left">Subjects gender (<italic>N</italic>)</td><td char="." align="char">10</td><td char="." align="char">13</td><td align="left"/><td align="left"/></tr><tr><td align="left">Male</td><td char="." align="char">5</td><td char="." align="char">11</td><td align="left"/><td align="left"/></tr><tr><td align="left">Female</td><td char="." align="char">5</td><td char="." align="char">2</td><td align="left"/><td align="left"/></tr></tbody></table>
###xml 1641 1641 1641 1641 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1641 1645 1641 1645 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean</th>
###xml 1645 1647 1645 1647 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SD</th>
###xml 1647 1651 1647 1651 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean</th>
###xml 1651 1653 1651 1653 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SD</th>
###xml 1641 1653 1641 1653 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr>
###xml 1641 1653 1641 1653 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr></thead>
###xml 1653 1673 1653 1673 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age at death (years)</td>
###xml 1673 1678 1673 1678 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">69.10</td>
###xml 1678 1683 1678 1683 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14.40</td>
###xml 1683 1688 1683 1688 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">64.54</td>
###xml 1688 1693 1688 1693 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13.58</td>
###xml 1653 1693 1653 1693 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age at death (years)</td><td char="." align="char">69.10</td><td char="." align="char">14.40</td><td char="." align="char">64.54</td><td char="." align="char">13.58</td></tr>
###xml 1693 1716 1693 1716 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Postmortem interval (h)</td>
###xml 1716 1721 1716 1721 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21.00</td>
###xml 1721 1726 1721 1726 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10.66</td>
###xml 1726 1731 1726 1731 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">23.85</td>
###xml 1731 1736 1731 1736 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">23.12</td>
###xml 1693 1736 1693 1736 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Postmortem interval (h)</td><td char="." align="char">21.00</td><td char="." align="char">10.66</td><td char="." align="char">23.85</td><td char="." align="char">23.12</td></tr>
###xml 1736 1738 1736 1738 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">pH</td>
###xml 1738 1742 1738 1742 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.42</td>
###xml 1742 1746 1742 1746 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.35</td>
###xml 1746 1750 1746 1750 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.65</td>
###xml 1750 1754 1750 1754 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.37</td>
###xml 1736 1754 1736 1754 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">pH</td><td char="." align="char">6.42</td><td char="." align="char">0.35</td><td char="." align="char">6.65</td><td char="." align="char">0.37</td></tr>
###xml 1754 1774 1754 1774 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age at onset (years)</td>
###xml 1774 1779 1774 1779 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24.60</td>
###xml 1779 1783 1779 1783 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.36</td>
###xml 1783 1783 1783 1783 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2"/>
###xml 1754 1783 1754 1783 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age at onset (years)</td><td char="." align="char">24.60</td><td char="." align="char">7.36</td><td align="left" colspan="2"/></tr>
###xml 1783 1810 1783 1810 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Duration of disease (years)</td>
###xml 1810 1815 1810 1815 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">43.20</td>
###xml 1815 1820 1815 1820 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11.57</td>
###xml 1820 1820 1820 1820 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2"/>
###xml 1783 1820 1783 1820 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Duration of disease (years)</td><td char="." align="char">43.20</td><td char="." align="char">11.57</td><td align="left" colspan="2"/></tr>
###xml 1820 1855 1820 1855 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Duration of hospitalization (years)</td>
###xml 1855 1860 1855 1860 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25.10</td>
###xml 1860 1865 1860 1865 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15.32</td>
###xml 1865 1865 1865 1865 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2"/>
###xml 1820 1865 1820 1865 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Duration of hospitalization (years)</td><td char="." align="char">25.10</td><td char="." align="char">15.32</td><td align="left" colspan="2"/></tr>
###xml 1865 1909 1865 1909 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Duration of antipsychotic medication (years)</td>
###xml 1909 1914 1909 1914 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">35.00</td>
###xml 1914 1918 1914 1918 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.72</td>
###xml 1918 1918 1918 1918 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2"/>
###xml 1865 1918 1865 1918 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Duration of antipsychotic medication (years)</td><td char="." align="char">35.00</td><td char="." align="char">9.72</td><td align="left" colspan="2"/></tr>
###xml 1918 1996 1918 1996 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Last dose of antipsychotic medication in chlorpromazine equivalents (CPE in g)</td>
###xml 1996 2002 1996 2002 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">686.26</td>
###xml 2002 2008 2002 2008 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">787.36</td>
###xml 2008 2008 2008 2008 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2"/>
###xml 1918 2008 1918 2008 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Last dose of antipsychotic medication in chlorpromazine equivalents (CPE in g)</td><td char="." align="char">686.26</td><td char="." align="char">787.36</td><td align="left" colspan="2"/></tr>
###xml 2008 2109 2008 2109 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cumulative dose (last 10&#160;years) of antipsychotic medication in chlorpromazine equivalents (CPE in kg)</td>
###xml 2109 2113 2109 2113 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.36</td>
###xml 2113 2117 2113 2117 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.19</td>
###xml 2117 2117 2117 2117 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2"/>
###xml 2008 2117 2008 2117 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Cumulative dose (last 10&#160;years) of antipsychotic medication in chlorpromazine equivalents (CPE in kg)</td><td char="." align="char">4.36</td><td char="." align="char">3.19</td><td align="left" colspan="2"/></tr>
###xml 1653 2117 1653 2117 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Age at death (years)</td><td char="." align="char">69.10</td><td char="." align="char">14.40</td><td char="." align="char">64.54</td><td char="." align="char">13.58</td></tr><tr><td align="left">Postmortem interval (h)</td><td char="." align="char">21.00</td><td char="." align="char">10.66</td><td char="." align="char">23.85</td><td char="." align="char">23.12</td></tr><tr><td align="left">pH</td><td char="." align="char">6.42</td><td char="." align="char">0.35</td><td char="." align="char">6.65</td><td char="." align="char">0.37</td></tr><tr><td align="left">Age at onset (years)</td><td char="." align="char">24.60</td><td char="." align="char">7.36</td><td align="left" colspan="2"/></tr><tr><td align="left">Duration of disease (years)</td><td char="." align="char">43.20</td><td char="." align="char">11.57</td><td align="left" colspan="2"/></tr><tr><td align="left">Duration of hospitalization (years)</td><td char="." align="char">25.10</td><td char="." align="char">15.32</td><td align="left" colspan="2"/></tr><tr><td align="left">Duration of antipsychotic medication (years)</td><td char="." align="char">35.00</td><td char="." align="char">9.72</td><td align="left" colspan="2"/></tr><tr><td align="left">Last dose of antipsychotic medication in chlorpromazine equivalents (CPE in g)</td><td char="." align="char">686.26</td><td char="." align="char">787.36</td><td align="left" colspan="2"/></tr><tr><td align="left">Cumulative dose (last 10&#160;years) of antipsychotic medication in chlorpromazine equivalents (CPE in kg)</td><td char="." align="char">4.36</td><td char="." align="char">3.19</td><td align="left" colspan="2"/></tr></tbody>
###xml 1641 2117 1641 2117 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr></thead><tbody><tr><td align="left">Age at death (years)</td><td char="." align="char">69.10</td><td char="." align="char">14.40</td><td char="." align="char">64.54</td><td char="." align="char">13.58</td></tr><tr><td align="left">Postmortem interval (h)</td><td char="." align="char">21.00</td><td char="." align="char">10.66</td><td char="." align="char">23.85</td><td char="." align="char">23.12</td></tr><tr><td align="left">pH</td><td char="." align="char">6.42</td><td char="." align="char">0.35</td><td char="." align="char">6.65</td><td char="." align="char">0.37</td></tr><tr><td align="left">Age at onset (years)</td><td char="." align="char">24.60</td><td char="." align="char">7.36</td><td align="left" colspan="2"/></tr><tr><td align="left">Duration of disease (years)</td><td char="." align="char">43.20</td><td char="." align="char">11.57</td><td align="left" colspan="2"/></tr><tr><td align="left">Duration of hospitalization (years)</td><td char="." align="char">25.10</td><td char="." align="char">15.32</td><td align="left" colspan="2"/></tr><tr><td align="left">Duration of antipsychotic medication (years)</td><td char="." align="char">35.00</td><td char="." align="char">9.72</td><td align="left" colspan="2"/></tr><tr><td align="left">Last dose of antipsychotic medication in chlorpromazine equivalents (CPE in g)</td><td char="." align="char">686.26</td><td char="." align="char">787.36</td><td align="left" colspan="2"/></tr><tr><td align="left">Cumulative dose (last 10&#160;years) of antipsychotic medication in chlorpromazine equivalents (CPE in kg)</td><td char="." align="char">4.36</td><td char="." align="char">3.19</td><td align="left" colspan="2"/></tr></tbody></table>
###xml 2117 2450 2117 2450 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="12">There were no statistically significant differences between age at time of death, post-mortem interval (PMI) and brain pH. Schizophrenia patients were characterized by duration of disease, duration of medication and medication (last dose) in chlorpromazine equivalents (CPE), as well as cumulative dose over the last ten years in CPE</p>
###xml 2117 2450 2117 2450 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="12">There were no statistically significant differences between age at time of death, post-mortem interval (PMI) and brain pH. Schizophrenia patients were characterized by duration of disease, duration of medication and medication (last dose) in chlorpromazine equivalents (CPE), as well as cumulative dose over the last ten years in CPE</p></table-wrap-foot>
###xml 1388 2450 1388 2450 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="11">Characteristics of post-mortem samples from patients with schizophrenia and normal comparison subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Tissue from patients with schizophrenia (<italic>n</italic>&#160;=&#160;10)</th><th align="left">Tissue from normal patient subjects (<italic>n</italic>&#160;=&#160;13)</th><th align="left"/><th align="left"/></tr></thead><tbody><tr><td align="left">Subjects gender (<italic>N</italic>)</td><td char="." align="char">10</td><td char="." align="char">13</td><td align="left"/><td align="left"/></tr><tr><td align="left">Male</td><td char="." align="char">5</td><td char="." align="char">11</td><td align="left"/><td align="left"/></tr><tr><td align="left">Female</td><td char="." align="char">5</td><td char="." align="char">2</td><td align="left"/><td align="left"/></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr></thead><tbody><tr><td align="left">Age at death (years)</td><td char="." align="char">69.10</td><td char="." align="char">14.40</td><td char="." align="char">64.54</td><td char="." align="char">13.58</td></tr><tr><td align="left">Postmortem interval (h)</td><td char="." align="char">21.00</td><td char="." align="char">10.66</td><td char="." align="char">23.85</td><td char="." align="char">23.12</td></tr><tr><td align="left">pH</td><td char="." align="char">6.42</td><td char="." align="char">0.35</td><td char="." align="char">6.65</td><td char="." align="char">0.37</td></tr><tr><td align="left">Age at onset (years)</td><td char="." align="char">24.60</td><td char="." align="char">7.36</td><td align="left" colspan="2"/></tr><tr><td align="left">Duration of disease (years)</td><td char="." align="char">43.20</td><td char="." align="char">11.57</td><td align="left" colspan="2"/></tr><tr><td align="left">Duration of hospitalization (years)</td><td char="." align="char">25.10</td><td char="." align="char">15.32</td><td align="left" colspan="2"/></tr><tr><td align="left">Duration of antipsychotic medication (years)</td><td char="." align="char">35.00</td><td char="." align="char">9.72</td><td align="left" colspan="2"/></tr><tr><td align="left">Last dose of antipsychotic medication in chlorpromazine equivalents (CPE in g)</td><td char="." align="char">686.26</td><td char="." align="char">787.36</td><td align="left" colspan="2"/></tr><tr><td align="left">Cumulative dose (last 10&#160;years) of antipsychotic medication in chlorpromazine equivalents (CPE in kg)</td><td char="." align="char">4.36</td><td char="." align="char">3.19</td><td align="left" colspan="2"/></tr></tbody></table><table-wrap-foot><p textid="12">There were no statistically significant differences between age at time of death, post-mortem interval (PMI) and brain pH. Schizophrenia patients were characterized by duration of disease, duration of medication and medication (last dose) in chlorpromazine equivalents (CPE), as well as cumulative dose over the last ten years in CPE</p></table-wrap-foot></table-wrap>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
###xml 1439 1447 <span type="species:ncbi:9606">patients</span>
###xml 1523 1531 <span type="species:ncbi:9606">patients</span>
###xml 1578 1585 <span type="species:ncbi:9606">patient</span>
###xml 2254 2262 <span type="species:ncbi:9606">patients</span>
We collected post-mortem brain samples from patients with DSM-IV residual schizophrenia (n = 10) and elderly comparison subjects (n = 13) who had been diagnosed using the DSM-IV checklist of the American Psychiatric Association (APA). Due to incomplete collection of the hippocampus, number of investigated cases ranged from 8 (right hemisphere) up to 10 (left hemisphere) in schizophrenia patients and 10 (right hemisphere) up to 13 (left hemisphere) in healthy probands. All schizophrenia patients had been long-term inpatients at the State Mental Hospital Wiesloch, Germany and had been diagnosed ante-mortem according to DSM IV criteria (American PA, 1994). After assessing patients' history of antipsychotic treatment by examining their medical charts, we then calculated the last dose as well as the cumulative dose during the last 10 years of antipsychotic medication in chlorpromazine equivalents (CPE) through the algorithm developed by Jahn and Mussgay (1989). Table 1 outlines the demographic variables. Controls were collected at the Institutes of Neuropathology, of the Universities of Heidelberg and Bonn and the respective clinical records obtained from their relatives and general practitioners. All assessments and post-mortem evaluations and procedures had been approved by the Ethics Committees of the Faculties of Medicine of Heidelberg and Bonn Universities, Germany.Table 1Characteristics of post-mortem samples from patients with schizophrenia and normal comparison subjectsCharacteristicTissue from patients with schizophrenia (n = 10)Tissue from normal patient subjects (n = 13)Subjects gender (N)1013Male511Female52MeanSDMeanSDAge at death (years)69.1014.4064.5413.58Postmortem interval (h)21.0010.6623.8523.12pH6.420.356.650.37Age at onset (years)24.607.36Duration of disease (years)43.2011.57Duration of hospitalization (years)25.1015.32Duration of antipsychotic medication (years)35.009.72Last dose of antipsychotic medication in chlorpromazine equivalents (CPE in g)686.26787.36Cumulative dose (last 10 years) of antipsychotic medication in chlorpromazine equivalents (CPE in kg)4.363.19There were no statistically significant differences between age at time of death, post-mortem interval (PMI) and brain pH. Schizophrenia patients were characterized by duration of disease, duration of medication and medication (last dose) in chlorpromazine equivalents (CPE), as well as cumulative dose over the last ten years in CPE
###end p 10
###begin p 11
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Characteristics of post-mortem samples from patients with schizophrenia and normal comparison subjects
###end p 11
###begin p 12
###xml 137 145 <span type="species:ncbi:9606">patients</span>
There were no statistically significant differences between age at time of death, post-mortem interval (PMI) and brain pH. Schizophrenia patients were characterized by duration of disease, duration of medication and medication (last dose) in chlorpromazine equivalents (CPE), as well as cumulative dose over the last ten years in CPE
###end p 12
###begin p 13
###xml 228 232 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">1991</xref>
###xml 247 251 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2006</xref>
###xml 617 618 617 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 635 636 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 655 656 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 678 679 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 699 700 699 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 721 722 721 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 742 743 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 764 765 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 789 790 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 807 808 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 829 830 829 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">Patients</span>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
All patients and controls underwent thorough neuropathologic characterization in order to rule out associated neurovascular or neurodegenerative disorders, such as Alzheimer s disease and multi-infarct dementia (Braak and Braak 1991; Braak et al. 2006). The staging according to Braak was 2 or less for all subjects. Patients and normal comparison subjects had no history of alcohol, drug abuse, or severe physical illness as for example carcinoma. Normal comparison subjects had no history of psychiatric disorders. All patients had been receiving long-term antipsychotic medication before death, such as clozapine (n = 3), zotepine (n = 1), olanzapine (n = 2), flupenthixole (n = 1), haloperidol (n = 3), perphenazine (n = 1), pipamperone (n = 1), promethazine (n = 1), zuclopenthixole (n = 1), perazine (n = 1), prothipendyl (n = 1).
###end p 13
###begin p 14
Post-mortem brains were dissected at the midline of the hemispheres. Tissue blocks were prepared from the granular frontal cortex (BA9), the middle frontal cortex (BA46), the superior temporal cortex (BA22), the entorhinal cortex (BA28), the sensoric cortex (BA1-3), the hippocampus cornu ammonis 4 (CA4), and the mediodorsal nucleus of the thalamus from the right and left hemisphere. Blocks were immediately snap-frozen in liquid nitrogen-cooled isopentane and stored at -80degreesC. From these, 10 mum sections were cut and were collected on coated slides. All material was coded and experiments were carried out by researchers who were blind to diagnosis.
###end p 14
###begin title 15
In situ-hybridization
###end title 15
###begin p 16
###xml 35 39 35 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">2005</xref>
###xml 97 99 97 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 862 864 862 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 961 962 961 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 152 157 <span type="species:ncbi:9606">human</span>
In situ-hybridization (Zink et al. 2005) was performed on two sections of each brain region with 35S-UTP-labeled cRNA-probes of the DAAO gene. RNA from human cerebral cortex (RNeasy, Qiagen, Hilden, Germany) was reverse transcribed with the reverse transcriptase Superscript II (Gibco Life-Technologies, Karlsruhe, Germany) and the oligo-dT-Primers (Perkin-Elmer, Wellesley, USA). After PCR-amplification (Promega, Mannheim, Germany) with specific primers derived from DAAO (bases 251-710 in Genbank NM 001917) the amplicons were subcloned into gGEM-T vector (Promega, Mannheim, Germany). Correct amplification and orientation were checked by commercial sequencing (MWG, Ebersberg, Germany). Linearized plasmids were transcribed in vitro with Sp6 or T7-RNA-polymerase (MBI-Fermentas, St Leon Roth, Germany). Efficiency of incorporation of radioactively labeled [35S]-UTP was measured and hybridizations with antisense- and sense-probes using concentration of 107 cpm/ml were carried out under high stringency conditions (55degreesC, 50% formamide) for 16 h. Hybridizations with sense-probes were intended as negative controls for specificity. After several washing steps including RNAse A-digestion, slices were dehydrated and were exposed to X-ray films (Biomax MR1 18 x 24 cm) for 2-6 days.
###end p 16
###begin title 17
Image analysis
###end title 17
###begin p 18
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 525 527 525 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 747 753 747 753 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 983 984 983 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1019 1020 1019 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 753 1101 753 1101 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19">Gene expression of DAAO in the hippocampus expressed as Bq/g brain tissue in the gray matter of the right and left hemisphere. Compared to the control group, we found a statistically significant increase in the expression of 46% (<italic>P</italic>&#160;=&#160;0.013) in the right and of 54% (<italic>P</italic>&#160;=&#160;0.019) in the left hemisphere of the hippocampal CA4 of schizophrenic patients</p>
###xml 753 1101 753 1101 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="19">Gene expression of DAAO in the hippocampus expressed as Bq/g brain tissue in the gray matter of the right and left hemisphere. Compared to the control group, we found a statistically significant increase in the expression of 46% (<italic>P</italic>&#160;=&#160;0.013) in the right and of 54% (<italic>P</italic>&#160;=&#160;0.019) in the left hemisphere of the hippocampal CA4 of schizophrenic patients</p></caption>
###xml 1101 1101 1101 1101 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2009_312_Fig1_HTML" id="MO1"/>
###xml 747 1101 747 1101 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="19">Gene expression of DAAO in the hippocampus expressed as Bq/g brain tissue in the gray matter of the right and left hemisphere. Compared to the control group, we found a statistically significant increase in the expression of 46% (<italic>P</italic>&#160;=&#160;0.013) in the right and of 54% (<italic>P</italic>&#160;=&#160;0.019) in the left hemisphere of the hippocampal CA4 of schizophrenic patients</p></caption><graphic position="anchor" xlink:href="702_2009_312_Fig1_HTML" id="MO1"/></fig>
###xml 1093 1101 <span type="species:ncbi:9606">patients</span>
Autoradiographic films (see representative examples of the hippocampus in Fig. 1) were analyzed with a video camera (Sony XC ST 70) and the AIS software (Applied Information Systems, Chapel Hill, USA). Non-specific signals were assessed separately for each section in the white matter separating hippocampal CA4 and cerebral cortex. These readings were subtracted from gray values in the regions of interest (total binding) resulting in a semiquantitative determination of mRNA-abundance. Gray value images of the co-exposed 14C-calibration standards (Amersham, Buckinghamshire, UK) were used to compute a calibration curve by non-linear least squares fitting, which defined the relationship between gray values and concentration of radioactivity.Fig. 1Gene expression of DAAO in the hippocampus expressed as Bq/g brain tissue in the gray matter of the right and left hemisphere. Compared to the control group, we found a statistically significant increase in the expression of 46% (P = 0.013) in the right and of 54% (P = 0.019) in the left hemisphere of the hippocampal CA4 of schizophrenic patients
###end p 18
###begin p 19
###xml 230 231 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 266 267 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
Gene expression of DAAO in the hippocampus expressed as Bq/g brain tissue in the gray matter of the right and left hemisphere. Compared to the control group, we found a statistically significant increase in the expression of 46% (P = 0.013) in the right and of 54% (P = 0.019) in the left hemisphere of the hippocampal CA4 of schizophrenic patients
###end p 19
###begin p 20
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">2009</xref>
###xml 342 346 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1999</xref>
We measured DAAO specific bindings in the cortical brain regions in both gray and white matter. In the hippocampus, the region of interest was the CA4 region. In the thalamus, we investigated the mediodorsal nucleus. Both regions were selected due to their impact in the pathophysiology of schizophrenia (Schmitt et al. 2009; Carlsson et al. 1999).
###end p 20
###begin title 21
Statistical analysis
###end title 21
###begin p 22
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical analyses were performed with SPSS 15. All tests were two-tailed. The level of significance was defined as P < 0.05. Distributions for all dependent variables were examined in both groups using histograms and the Kolmogorov-Smirnov test on normality. Due to our small sample size, the power for the Kolmogorov-Smirnov test was not very high. Nonetheless, our results suggest a normal distribution of the data and analysis by parametric tests.
###end p 22
###begin p 23
###xml 506 514 <span type="species:ncbi:9606">patients</span>
In all regions analyzed, we first performed oneway analyses of variance (ANOVA) with diagnostic group as independent factor. Additionally, we assessed correlations between the dependent and intervening variables age, PMI, brain pH, disease duration, dose, and duration of medication using Spearmen rank correlation coefficients, as some of the intervening variables like PMI and medication dose deviated significantly from normal distribution. These correlations were computed separately for schizophrenia patients and-if present-for controls. In all regions, oneway ANOVA with factor gender was calculated to analyze if specific bindings differed between male and female subjects. As in these initial analyses, age and PMI showed a significant influence on specific bindings in the hippocampal region, we performed analyses of covariance (ANCOVA) with diagnostic group as independent factor and age and PMI as covariates.
###end p 23
###begin p 24
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
This is an explorative study aimed at finding variables that may show differences in the expression of DAAO-mRNA between schizophrenia patients and control subjects. If a Bonferroni adjustment of the error probability of first kind for the number of statistical tests was applied, no significant differences between schizophrenia patients and controls would remain. However, one must keep in mind that adjustment of the error probability would decrease the power of the test to such an extent that the power of detecting existing mean differences would be very low. Thus, the present results are presented without error probability correction. Due to our explorative study design and the problems of multiple testing, these findings offer no conclusive evidence for a causal relationship. An independent larger sample has to be analyzed in an effort to confirm the positive findings of this study.
###end p 24
###begin title 25
Results
###end title 25
###begin p 26
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 306 308 306 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 317 318 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 433 434 433 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 442 444 442 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 452 453 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 551 552 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 560 562 560 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 571 572 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 586 587 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 595 597 595 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 622 623 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 631 633 631 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 642 643 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 666 667 664 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 676 678 674 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 684 685 682 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 695 702 693 700 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 702 876 700 872 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Descriptive Statistics for specific bindings (mean&#160;&#177;&#160;standard deviation) expressed in Bq/g brain tissue in the analyzed brain regions in schizophrenic patients and controls</p>
###xml 702 876 700 872 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">Descriptive Statistics for specific bindings (mean&#160;&#177;&#160;standard deviation) expressed in Bq/g brain tissue in the analyzed brain regions in schizophrenic patients and controls</p></caption>
###xml 876 882 872 878 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Region</th>
###xml 882 897 878 893 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Left hemisphere</th>
###xml 897 913 893 909 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Right hemisphere</th>
###xml 876 913 872 909 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Region</th><th align="left" colspan="2">Left hemisphere</th><th align="left" colspan="2">Right hemisphere</th></tr>
###xml 913 920 909 916 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control</th>
###xml 920 933 916 929 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Schizophrenia</th>
###xml 933 940 929 936 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Control</th>
###xml 940 953 936 949 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Schizophrenia</th>
###xml 913 953 909 949 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Control</th><th align="left">Schizophrenia</th><th align="left">Control</th><th align="left">Schizophrenia</th></tr>
###xml 953 964 949 958 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean&#160;&#177;&#160;SD</th>
###xml 964 975 958 967 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean&#160;&#177;&#160;SD</th>
###xml 975 986 967 976 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean&#160;&#177;&#160;SD</th>
###xml 986 997 976 985 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean&#160;&#177;&#160;SD</th>
###xml 953 997 949 985 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th></tr>
###xml 876 997 872 985 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3">Region</th><th align="left" colspan="2">Left hemisphere</th><th align="left" colspan="2">Right hemisphere</th></tr><tr><th align="left">Control</th><th align="left">Schizophrenia</th><th align="left">Control</th><th align="left">Schizophrenia</th></tr><tr><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th></tr></thead>
###xml 997 1039 985 1027 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA9 granular frontal cortex (white matter)</td>
###xml 1039 1050 1027 1036 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">579&#160;&#177;&#160;215</td>
###xml 1050 1061 1036 1045 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">595&#160;&#177;&#160;174</td>
###xml 1061 1071 1045 1053 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">837&#160;&#177;&#160;85</td>
###xml 1071 1082 1053 1062 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">594&#160;&#177;&#160;252</td>
###xml 997 1082 985 1062 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA9 granular frontal cortex (white matter)</td><td char="&#177;" align="char">579&#160;&#177;&#160;215</td><td char="&#177;" align="char">595&#160;&#177;&#160;174</td><td char="&#177;" align="char">837&#160;&#177;&#160;85</td><td char="&#177;" align="char">594&#160;&#177;&#160;252</td></tr>
###xml 1082 1123 1062 1103 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA9 granular frontal cortex (gray matter)</td>
###xml 1123 1134 1103 1112 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">452&#160;&#177;&#160;190</td>
###xml 1134 1145 1112 1121 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">428&#160;&#177;&#160;145</td>
###xml 1145 1156 1121 1130 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">494&#160;&#177;&#160;172</td>
###xml 1156 1167 1130 1139 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">437&#160;&#177;&#160;181</td>
###xml 1082 1167 1062 1139 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA9 granular frontal cortex (gray matter)</td><td char="&#177;" align="char">452&#160;&#177;&#160;190</td><td char="&#177;" align="char">428&#160;&#177;&#160;145</td><td char="&#177;" align="char">494&#160;&#177;&#160;172</td><td char="&#177;" align="char">437&#160;&#177;&#160;181</td></tr>
###xml 1167 1208 1139 1180 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA46 middle frontal cortex (white matter)</td>
###xml 1208 1217 1180 1187 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">692&#160;&#177;&#160;0</td>
###xml 1217 1228 1187 1196 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">745&#160;&#177;&#160;138</td>
###xml 1228 1237 1196 1203 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">717&#160;&#177;&#160;0</td>
###xml 1237 1248 1203 1212 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">691&#160;&#177;&#160;230</td>
###xml 1167 1248 1139 1212 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA46 middle frontal cortex (white matter)</td><td char="&#177;" align="char">692&#160;&#177;&#160;0</td><td char="&#177;" align="char">745&#160;&#177;&#160;138</td><td char="&#177;" align="char">717&#160;&#177;&#160;0</td><td char="&#177;" align="char">691&#160;&#177;&#160;230</td></tr>
###xml 1248 1288 1212 1252 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA46 middle frontal cortex (gray matter)</td>
###xml 1288 1299 1252 1261 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">466&#160;&#177;&#160;159</td>
###xml 1299 1310 1261 1270 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">573&#160;&#177;&#160;125</td>
###xml 1310 1321 1270 1279 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">572&#160;&#177;&#160;207</td>
###xml 1321 1332 1279 1288 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">549&#160;&#177;&#160;191</td>
###xml 1248 1332 1212 1288 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA46 middle frontal cortex (gray matter)</td><td char="&#177;" align="char">466&#160;&#177;&#160;159</td><td char="&#177;" align="char">573&#160;&#177;&#160;125</td><td char="&#177;" align="char">572&#160;&#177;&#160;207</td><td char="&#177;" align="char">549&#160;&#177;&#160;191</td></tr>
###xml 1332 1376 1288 1332 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA22 superior temporal cortex (white matter)</td>
###xml 1376 1385 1332 1339 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">527&#160;&#177;&#160;0</td>
###xml 1385 1395 1339 1347 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">523&#160;&#177;&#160;63</td>
###xml 1395 1406 1347 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">696&#160;&#177;&#160;259</td>
###xml 1406 1416 1356 1364 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">475&#160;&#177;&#160;72</td>
###xml 1332 1416 1288 1364 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA22 superior temporal cortex (white matter)</td><td char="&#177;" align="char">527&#160;&#177;&#160;0</td><td char="&#177;" align="char">523&#160;&#177;&#160;63</td><td char="&#177;" align="char">696&#160;&#177;&#160;259</td><td char="&#177;" align="char">475&#160;&#177;&#160;72</td></tr>
###xml 1416 1459 1364 1407 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA22 superior temporal cortex (gray matter)</td>
###xml 1459 1470 1407 1416 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">418&#160;&#177;&#160;152</td>
###xml 1470 1481 1416 1425 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">644&#160;&#177;&#160;297</td>
###xml 1481 1492 1425 1434 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">551&#160;&#177;&#160;192</td>
###xml 1492 1503 1434 1443 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">549&#160;&#177;&#160;199</td>
###xml 1416 1503 1364 1443 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA22 superior temporal cortex (gray matter)</td><td char="&#177;" align="char">418&#160;&#177;&#160;152</td><td char="&#177;" align="char">644&#160;&#177;&#160;297</td><td char="&#177;" align="char">551&#160;&#177;&#160;192</td><td char="&#177;" align="char">549&#160;&#177;&#160;199</td></tr>
###xml 1503 1539 1443 1479 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA1&#8211;3 sensoric cortex (white matter)</td>
###xml 1539 1550 1479 1488 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">471&#160;&#177;&#160;187</td>
###xml 1550 1561 1488 1497 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">597&#160;&#177;&#160;155</td>
###xml 1561 1572 1497 1506 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">621&#160;&#177;&#160;280</td>
###xml 1572 1583 1506 1515 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">549&#160;&#177;&#160;224</td>
###xml 1503 1583 1443 1515 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA1&#8211;3 sensoric cortex (white matter)</td><td char="&#177;" align="char">471&#160;&#177;&#160;187</td><td char="&#177;" align="char">597&#160;&#177;&#160;155</td><td char="&#177;" align="char">621&#160;&#177;&#160;280</td><td char="&#177;" align="char">549&#160;&#177;&#160;224</td></tr>
###xml 1583 1618 1515 1550 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA1&#8211;3 sensoric cortex (gray matter)</td>
###xml 1618 1629 1550 1559 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">410&#160;&#177;&#160;179</td>
###xml 1629 1640 1559 1568 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">491&#160;&#177;&#160;234</td>
###xml 1640 1651 1568 1577 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">476&#160;&#177;&#160;191</td>
###xml 1651 1662 1577 1586 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">438&#160;&#177;&#160;185</td>
###xml 1583 1662 1515 1586 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA1&#8211;3 sensoric cortex (gray matter)</td><td char="&#177;" align="char">410&#160;&#177;&#160;179</td><td char="&#177;" align="char">491&#160;&#177;&#160;234</td><td char="&#177;" align="char">476&#160;&#177;&#160;191</td><td char="&#177;" align="char">438&#160;&#177;&#160;185</td></tr>
###xml 1662 1679 1586 1603 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hippocampus (CA4)</td>
###xml 1679 1689 1603 1611 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">401&#160;&#177;&#160;42</td>
###xml 1689 1701 1611 1621 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">619&#160;&#177;&#160;197*</td>
###xml 1701 1711 1621 1629 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">353&#160;&#177;&#160;84</td>
###xml 1711 1723 1629 1639 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">515&#160;&#177;&#160;137*</td>
###xml 1662 1723 1586 1639 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Hippocampus (CA4)</td><td char="&#177;" align="char">401&#160;&#177;&#160;42</td><td char="&#177;" align="char">619&#160;&#177;&#160;197*</td><td char="&#177;" align="char">353&#160;&#177;&#160;84</td><td char="&#177;" align="char">515&#160;&#177;&#160;137*</td></tr>
###xml 1723 1760 1639 1676 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA28 entorhinal cortex (white matter)</td>
###xml 1760 1771 1676 1685 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">624&#160;&#177;&#160;281</td>
###xml 1771 1782 1685 1694 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">724&#160;&#177;&#160;206</td>
###xml 1782 1793 1694 1703 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">740&#160;&#177;&#160;302</td>
###xml 1793 1804 1703 1712 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">499&#160;&#177;&#160;379</td>
###xml 1723 1804 1639 1712 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA28 entorhinal cortex (white matter)</td><td char="&#177;" align="char">624&#160;&#177;&#160;281</td><td char="&#177;" align="char">724&#160;&#177;&#160;206</td><td char="&#177;" align="char">740&#160;&#177;&#160;302</td><td char="&#177;" align="char">499&#160;&#177;&#160;379</td></tr>
###xml 1804 1840 1712 1748 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BA28 entorhinal cortex (gray matter)</td>
###xml 1840 1851 1748 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">559&#160;&#177;&#160;234</td>
###xml 1851 1862 1757 1766 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">582&#160;&#177;&#160;248</td>
###xml 1862 1873 1766 1775 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">556&#160;&#177;&#160;243</td>
###xml 1873 1884 1775 1784 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">550&#160;&#177;&#160;265</td>
###xml 1804 1884 1712 1784 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BA28 entorhinal cortex (gray matter)</td><td char="&#177;" align="char">559&#160;&#177;&#160;234</td><td char="&#177;" align="char">582&#160;&#177;&#160;248</td><td char="&#177;" align="char">556&#160;&#177;&#160;243</td><td char="&#177;" align="char">550&#160;&#177;&#160;265</td></tr>
###xml 1884 1914 1784 1814 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Thalamus (mediodorsal nucleus)</td>
###xml 1914 1925 1814 1823 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">424&#160;&#177;&#160;115</td>
###xml 1925 1936 1823 1832 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">450&#160;&#177;&#160;156</td>
###xml 1936 1946 1832 1840 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">369&#160;&#177;&#160;84</td>
###xml 1946 1957 1840 1849 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">363&#160;&#177;&#160;157</td>
###xml 1884 1957 1784 1849 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Thalamus (mediodorsal nucleus)</td><td char="&#177;" align="char">424&#160;&#177;&#160;115</td><td char="&#177;" align="char">450&#160;&#177;&#160;156</td><td char="&#177;" align="char">369&#160;&#177;&#160;84</td><td char="&#177;" align="char">363&#160;&#177;&#160;157</td></tr>
###xml 997 1957 985 1849 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">BA9 granular frontal cortex (white matter)</td><td char="&#177;" align="char">579&#160;&#177;&#160;215</td><td char="&#177;" align="char">595&#160;&#177;&#160;174</td><td char="&#177;" align="char">837&#160;&#177;&#160;85</td><td char="&#177;" align="char">594&#160;&#177;&#160;252</td></tr><tr><td align="left">BA9 granular frontal cortex (gray matter)</td><td char="&#177;" align="char">452&#160;&#177;&#160;190</td><td char="&#177;" align="char">428&#160;&#177;&#160;145</td><td char="&#177;" align="char">494&#160;&#177;&#160;172</td><td char="&#177;" align="char">437&#160;&#177;&#160;181</td></tr><tr><td align="left">BA46 middle frontal cortex (white matter)</td><td char="&#177;" align="char">692&#160;&#177;&#160;0</td><td char="&#177;" align="char">745&#160;&#177;&#160;138</td><td char="&#177;" align="char">717&#160;&#177;&#160;0</td><td char="&#177;" align="char">691&#160;&#177;&#160;230</td></tr><tr><td align="left">BA46 middle frontal cortex (gray matter)</td><td char="&#177;" align="char">466&#160;&#177;&#160;159</td><td char="&#177;" align="char">573&#160;&#177;&#160;125</td><td char="&#177;" align="char">572&#160;&#177;&#160;207</td><td char="&#177;" align="char">549&#160;&#177;&#160;191</td></tr><tr><td align="left">BA22 superior temporal cortex (white matter)</td><td char="&#177;" align="char">527&#160;&#177;&#160;0</td><td char="&#177;" align="char">523&#160;&#177;&#160;63</td><td char="&#177;" align="char">696&#160;&#177;&#160;259</td><td char="&#177;" align="char">475&#160;&#177;&#160;72</td></tr><tr><td align="left">BA22 superior temporal cortex (gray matter)</td><td char="&#177;" align="char">418&#160;&#177;&#160;152</td><td char="&#177;" align="char">644&#160;&#177;&#160;297</td><td char="&#177;" align="char">551&#160;&#177;&#160;192</td><td char="&#177;" align="char">549&#160;&#177;&#160;199</td></tr><tr><td align="left">BA1&#8211;3 sensoric cortex (white matter)</td><td char="&#177;" align="char">471&#160;&#177;&#160;187</td><td char="&#177;" align="char">597&#160;&#177;&#160;155</td><td char="&#177;" align="char">621&#160;&#177;&#160;280</td><td char="&#177;" align="char">549&#160;&#177;&#160;224</td></tr><tr><td align="left">BA1&#8211;3 sensoric cortex (gray matter)</td><td char="&#177;" align="char">410&#160;&#177;&#160;179</td><td char="&#177;" align="char">491&#160;&#177;&#160;234</td><td char="&#177;" align="char">476&#160;&#177;&#160;191</td><td char="&#177;" align="char">438&#160;&#177;&#160;185</td></tr><tr><td align="left">Hippocampus (CA4)</td><td char="&#177;" align="char">401&#160;&#177;&#160;42</td><td char="&#177;" align="char">619&#160;&#177;&#160;197*</td><td char="&#177;" align="char">353&#160;&#177;&#160;84</td><td char="&#177;" align="char">515&#160;&#177;&#160;137*</td></tr><tr><td align="left">BA28 entorhinal cortex (white matter)</td><td char="&#177;" align="char">624&#160;&#177;&#160;281</td><td char="&#177;" align="char">724&#160;&#177;&#160;206</td><td char="&#177;" align="char">740&#160;&#177;&#160;302</td><td char="&#177;" align="char">499&#160;&#177;&#160;379</td></tr><tr><td align="left">BA28 entorhinal cortex (gray matter)</td><td char="&#177;" align="char">559&#160;&#177;&#160;234</td><td char="&#177;" align="char">582&#160;&#177;&#160;248</td><td char="&#177;" align="char">556&#160;&#177;&#160;243</td><td char="&#177;" align="char">550&#160;&#177;&#160;265</td></tr><tr><td align="left">Thalamus (mediodorsal nucleus)</td><td char="&#177;" align="char">424&#160;&#177;&#160;115</td><td char="&#177;" align="char">450&#160;&#177;&#160;156</td><td char="&#177;" align="char">369&#160;&#177;&#160;84</td><td char="&#177;" align="char">363&#160;&#177;&#160;157</td></tr></tbody>
###xml 876 1957 872 1849 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Region</th><th align="left" colspan="2">Left hemisphere</th><th align="left" colspan="2">Right hemisphere</th></tr><tr><th align="left">Control</th><th align="left">Schizophrenia</th><th align="left">Control</th><th align="left">Schizophrenia</th></tr><tr><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th></tr></thead><tbody><tr><td align="left">BA9 granular frontal cortex (white matter)</td><td char="&#177;" align="char">579&#160;&#177;&#160;215</td><td char="&#177;" align="char">595&#160;&#177;&#160;174</td><td char="&#177;" align="char">837&#160;&#177;&#160;85</td><td char="&#177;" align="char">594&#160;&#177;&#160;252</td></tr><tr><td align="left">BA9 granular frontal cortex (gray matter)</td><td char="&#177;" align="char">452&#160;&#177;&#160;190</td><td char="&#177;" align="char">428&#160;&#177;&#160;145</td><td char="&#177;" align="char">494&#160;&#177;&#160;172</td><td char="&#177;" align="char">437&#160;&#177;&#160;181</td></tr><tr><td align="left">BA46 middle frontal cortex (white matter)</td><td char="&#177;" align="char">692&#160;&#177;&#160;0</td><td char="&#177;" align="char">745&#160;&#177;&#160;138</td><td char="&#177;" align="char">717&#160;&#177;&#160;0</td><td char="&#177;" align="char">691&#160;&#177;&#160;230</td></tr><tr><td align="left">BA46 middle frontal cortex (gray matter)</td><td char="&#177;" align="char">466&#160;&#177;&#160;159</td><td char="&#177;" align="char">573&#160;&#177;&#160;125</td><td char="&#177;" align="char">572&#160;&#177;&#160;207</td><td char="&#177;" align="char">549&#160;&#177;&#160;191</td></tr><tr><td align="left">BA22 superior temporal cortex (white matter)</td><td char="&#177;" align="char">527&#160;&#177;&#160;0</td><td char="&#177;" align="char">523&#160;&#177;&#160;63</td><td char="&#177;" align="char">696&#160;&#177;&#160;259</td><td char="&#177;" align="char">475&#160;&#177;&#160;72</td></tr><tr><td align="left">BA22 superior temporal cortex (gray matter)</td><td char="&#177;" align="char">418&#160;&#177;&#160;152</td><td char="&#177;" align="char">644&#160;&#177;&#160;297</td><td char="&#177;" align="char">551&#160;&#177;&#160;192</td><td char="&#177;" align="char">549&#160;&#177;&#160;199</td></tr><tr><td align="left">BA1&#8211;3 sensoric cortex (white matter)</td><td char="&#177;" align="char">471&#160;&#177;&#160;187</td><td char="&#177;" align="char">597&#160;&#177;&#160;155</td><td char="&#177;" align="char">621&#160;&#177;&#160;280</td><td char="&#177;" align="char">549&#160;&#177;&#160;224</td></tr><tr><td align="left">BA1&#8211;3 sensoric cortex (gray matter)</td><td char="&#177;" align="char">410&#160;&#177;&#160;179</td><td char="&#177;" align="char">491&#160;&#177;&#160;234</td><td char="&#177;" align="char">476&#160;&#177;&#160;191</td><td char="&#177;" align="char">438&#160;&#177;&#160;185</td></tr><tr><td align="left">Hippocampus (CA4)</td><td char="&#177;" align="char">401&#160;&#177;&#160;42</td><td char="&#177;" align="char">619&#160;&#177;&#160;197*</td><td char="&#177;" align="char">353&#160;&#177;&#160;84</td><td char="&#177;" align="char">515&#160;&#177;&#160;137*</td></tr><tr><td align="left">BA28 entorhinal cortex (white matter)</td><td char="&#177;" align="char">624&#160;&#177;&#160;281</td><td char="&#177;" align="char">724&#160;&#177;&#160;206</td><td char="&#177;" align="char">740&#160;&#177;&#160;302</td><td char="&#177;" align="char">499&#160;&#177;&#160;379</td></tr><tr><td align="left">BA28 entorhinal cortex (gray matter)</td><td char="&#177;" align="char">559&#160;&#177;&#160;234</td><td char="&#177;" align="char">582&#160;&#177;&#160;248</td><td char="&#177;" align="char">556&#160;&#177;&#160;243</td><td char="&#177;" align="char">550&#160;&#177;&#160;265</td></tr><tr><td align="left">Thalamus (mediodorsal nucleus)</td><td char="&#177;" align="char">424&#160;&#177;&#160;115</td><td char="&#177;" align="char">450&#160;&#177;&#160;156</td><td char="&#177;" align="char">369&#160;&#177;&#160;84</td><td char="&#177;" align="char">363&#160;&#177;&#160;157</td></tr></tbody></table>
###xml 2021 2022 1913 1914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1957 2030 1849 1922 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Significant differences have been detected in hippocampal CA4 (*<italic>P</italic>&#160;&lt;&#160;0.05)</p>
###xml 1957 2030 1849 1922 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Significant differences have been detected in hippocampal CA4 (*<italic>P</italic>&#160;&lt;&#160;0.05)</p></table-wrap-foot>
###xml 695 2030 693 1922 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="27">Descriptive Statistics for specific bindings (mean&#160;&#177;&#160;standard deviation) expressed in Bq/g brain tissue in the analyzed brain regions in schizophrenic patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Region</th><th align="left" colspan="2">Left hemisphere</th><th align="left" colspan="2">Right hemisphere</th></tr><tr><th align="left">Control</th><th align="left">Schizophrenia</th><th align="left">Control</th><th align="left">Schizophrenia</th></tr><tr><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th><th align="left">Mean&#160;&#177;&#160;SD</th></tr></thead><tbody><tr><td align="left">BA9 granular frontal cortex (white matter)</td><td char="&#177;" align="char">579&#160;&#177;&#160;215</td><td char="&#177;" align="char">595&#160;&#177;&#160;174</td><td char="&#177;" align="char">837&#160;&#177;&#160;85</td><td char="&#177;" align="char">594&#160;&#177;&#160;252</td></tr><tr><td align="left">BA9 granular frontal cortex (gray matter)</td><td char="&#177;" align="char">452&#160;&#177;&#160;190</td><td char="&#177;" align="char">428&#160;&#177;&#160;145</td><td char="&#177;" align="char">494&#160;&#177;&#160;172</td><td char="&#177;" align="char">437&#160;&#177;&#160;181</td></tr><tr><td align="left">BA46 middle frontal cortex (white matter)</td><td char="&#177;" align="char">692&#160;&#177;&#160;0</td><td char="&#177;" align="char">745&#160;&#177;&#160;138</td><td char="&#177;" align="char">717&#160;&#177;&#160;0</td><td char="&#177;" align="char">691&#160;&#177;&#160;230</td></tr><tr><td align="left">BA46 middle frontal cortex (gray matter)</td><td char="&#177;" align="char">466&#160;&#177;&#160;159</td><td char="&#177;" align="char">573&#160;&#177;&#160;125</td><td char="&#177;" align="char">572&#160;&#177;&#160;207</td><td char="&#177;" align="char">549&#160;&#177;&#160;191</td></tr><tr><td align="left">BA22 superior temporal cortex (white matter)</td><td char="&#177;" align="char">527&#160;&#177;&#160;0</td><td char="&#177;" align="char">523&#160;&#177;&#160;63</td><td char="&#177;" align="char">696&#160;&#177;&#160;259</td><td char="&#177;" align="char">475&#160;&#177;&#160;72</td></tr><tr><td align="left">BA22 superior temporal cortex (gray matter)</td><td char="&#177;" align="char">418&#160;&#177;&#160;152</td><td char="&#177;" align="char">644&#160;&#177;&#160;297</td><td char="&#177;" align="char">551&#160;&#177;&#160;192</td><td char="&#177;" align="char">549&#160;&#177;&#160;199</td></tr><tr><td align="left">BA1&#8211;3 sensoric cortex (white matter)</td><td char="&#177;" align="char">471&#160;&#177;&#160;187</td><td char="&#177;" align="char">597&#160;&#177;&#160;155</td><td char="&#177;" align="char">621&#160;&#177;&#160;280</td><td char="&#177;" align="char">549&#160;&#177;&#160;224</td></tr><tr><td align="left">BA1&#8211;3 sensoric cortex (gray matter)</td><td char="&#177;" align="char">410&#160;&#177;&#160;179</td><td char="&#177;" align="char">491&#160;&#177;&#160;234</td><td char="&#177;" align="char">476&#160;&#177;&#160;191</td><td char="&#177;" align="char">438&#160;&#177;&#160;185</td></tr><tr><td align="left">Hippocampus (CA4)</td><td char="&#177;" align="char">401&#160;&#177;&#160;42</td><td char="&#177;" align="char">619&#160;&#177;&#160;197*</td><td char="&#177;" align="char">353&#160;&#177;&#160;84</td><td char="&#177;" align="char">515&#160;&#177;&#160;137*</td></tr><tr><td align="left">BA28 entorhinal cortex (white matter)</td><td char="&#177;" align="char">624&#160;&#177;&#160;281</td><td char="&#177;" align="char">724&#160;&#177;&#160;206</td><td char="&#177;" align="char">740&#160;&#177;&#160;302</td><td char="&#177;" align="char">499&#160;&#177;&#160;379</td></tr><tr><td align="left">BA28 entorhinal cortex (gray matter)</td><td char="&#177;" align="char">559&#160;&#177;&#160;234</td><td char="&#177;" align="char">582&#160;&#177;&#160;248</td><td char="&#177;" align="char">556&#160;&#177;&#160;243</td><td char="&#177;" align="char">550&#160;&#177;&#160;265</td></tr><tr><td align="left">Thalamus (mediodorsal nucleus)</td><td char="&#177;" align="char">424&#160;&#177;&#160;115</td><td char="&#177;" align="char">450&#160;&#177;&#160;156</td><td char="&#177;" align="char">369&#160;&#177;&#160;84</td><td char="&#177;" align="char">363&#160;&#177;&#160;157</td></tr></tbody></table><table-wrap-foot><p textid="28">Significant differences have been detected in hippocampal CA4 (*<italic>P</italic>&#160;&lt;&#160;0.05)</p></table-wrap-foot></table-wrap>
###xml 2030 2036 1922 1928 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 2132 2135 2024 2025 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 2175 2177 2065 2067 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 2239 2240 2129 2130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 2258 2259 2148 2149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 2316 2325 2206 2215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rectangle</italic>
###xml 2373 2375 2263 2265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DG</italic>
###xml 2036 2376 1928 2266 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Exemplary X-ray film analysis obtained from the computer program AIS (Analytical Imaging Station<sup>&#174;</sup> from Interfocus). The intensity of the <sup>35</sup>[S]-isotope was measured in Bq/g brain tissue. On the slides (<italic>1</italic> left hemisphere, <italic>2</italic> right hemisphere) we marked our region of interest CA4 (<italic>rectangle</italic>) and the subregions CA3 and the dentate gyrus (<italic>DG</italic>)</p>
###xml 2036 2376 1928 2266 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Exemplary X-ray film analysis obtained from the computer program AIS (Analytical Imaging Station<sup>&#174;</sup> from Interfocus). The intensity of the <sup>35</sup>[S]-isotope was measured in Bq/g brain tissue. On the slides (<italic>1</italic> left hemisphere, <italic>2</italic> right hemisphere) we marked our region of interest CA4 (<italic>rectangle</italic>) and the subregions CA3 and the dentate gyrus (<italic>DG</italic>)</p></caption>
###xml 2376 2376 2266 2266 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2009_312_Fig2_HTML" id="MO2"/>
###xml 2030 2376 1922 2266 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="29">Exemplary X-ray film analysis obtained from the computer program AIS (Analytical Imaging Station<sup>&#174;</sup> from Interfocus). The intensity of the <sup>35</sup>[S]-isotope was measured in Bq/g brain tissue. On the slides (<italic>1</italic> left hemisphere, <italic>2</italic> right hemisphere) we marked our region of interest CA4 (<italic>rectangle</italic>) and the subregions CA3 and the dentate gyrus (<italic>DG</italic>)</p></caption><graphic position="anchor" xlink:href="702_2009_312_Fig2_HTML" id="MO2"/></fig>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 496 504 <span type="species:ncbi:9606">patients</span>
###xml 855 863 <span type="species:ncbi:9606">patients</span>
Descriptives for specific bindings in the analyzed regions are shown in Table 2. In the present study, the hippocampal CA4 of schizophrenia patients revealed a significant increased expression of DAAO-mRNA in both hemispheres. Compared to the control group, we noted a 46% increase in expression (F = 6.5; df = 1,10; P = 0.029) in the right CA4 of schizophrenia patients (Fig. 1) and an increase of 54% of DAAO-mRNA in the left CA4 (F = 5.8; df = 1,9; P = 0.039) in ANOVA (Fig. 2). Schizophrenia patients did not differ from controls in terms of age (F = 0.6; df = 1,21; P = 0.45), pH (F = 0.5; df = 1,20, P = 0.68), PMI (F = 0.1; df = 1,21; P = 0.72) or gender (chi2 = 3.20; df = 1; P = 0.074).Table 2Descriptive Statistics for specific bindings (mean +/- standard deviation) expressed in Bq/g brain tissue in the analyzed brain regions in schizophrenic patients and controlsRegionLeft hemisphereRight hemisphereControlSchizophreniaControlSchizophreniaMean +/- SDMean +/- SDMean +/- SDMean +/- SDBA9 granular frontal cortex (white matter)579 +/- 215595 +/- 174837 +/- 85594 +/- 252BA9 granular frontal cortex (gray matter)452 +/- 190428 +/- 145494 +/- 172437 +/- 181BA46 middle frontal cortex (white matter)692 +/- 0745 +/- 138717 +/- 0691 +/- 230BA46 middle frontal cortex (gray matter)466 +/- 159573 +/- 125572 +/- 207549 +/- 191BA22 superior temporal cortex (white matter)527 +/- 0523 +/- 63696 +/- 259475 +/- 72BA22 superior temporal cortex (gray matter)418 +/- 152644 +/- 297551 +/- 192549 +/- 199BA1-3 sensoric cortex (white matter)471 +/- 187597 +/- 155621 +/- 280549 +/- 224BA1-3 sensoric cortex (gray matter)410 +/- 179491 +/- 234476 +/- 191438 +/- 185Hippocampus (CA4)401 +/- 42619 +/- 197*353 +/- 84515 +/- 137*BA28 entorhinal cortex (white matter)624 +/- 281724 +/- 206740 +/- 302499 +/- 379BA28 entorhinal cortex (gray matter)559 +/- 234582 +/- 248556 +/- 243550 +/- 265Thalamus (mediodorsal nucleus)424 +/- 115450 +/- 156369 +/- 84363 +/- 157Significant differences have been detected in hippocampal CA4 (*P < 0.05)Fig. 2Exemplary X-ray film analysis obtained from the computer program AIS (Analytical Imaging Station(R) from Interfocus). The intensity of the 35[S]-isotope was measured in Bq/g brain tissue. On the slides (1 left hemisphere, 2 right hemisphere) we marked our region of interest CA4 (rectangle) and the subregions CA3 and the dentate gyrus (DG)
###end p 26
###begin p 27
###xml 153 161 <span type="species:ncbi:9606">patients</span>
Descriptive Statistics for specific bindings (mean +/- standard deviation) expressed in Bq/g brain tissue in the analyzed brain regions in schizophrenic patients and controls
###end p 27
###begin p 28
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Significant differences have been detected in hippocampal CA4 (*P < 0.05)
###end p 28
###begin p 29
###xml 96 99 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 139 141 137 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 203 204 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 222 223 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 280 289 278 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rectangle</italic>
###xml 337 339 335 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DG</italic>
Exemplary X-ray film analysis obtained from the computer program AIS (Analytical Imaging Station(R) from Interfocus). The intensity of the 35[S]-isotope was measured in Bq/g brain tissue. On the slides (1 left hemisphere, 2 right hemisphere) we marked our region of interest CA4 (rectangle) and the subregions CA3 and the dentate gyrus (DG)
###end p 29
###begin p 30
###xml 520 521 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
In all other regions assessed [the granular frontal cortex (BA9), the middle frontal cortex (BA46), the superior temporal cortex (BA22), the entorhinal cortex (BA28), the sensoric cortex (BA1-3), and the mediodorsal nucleus of the thalamus], we saw no statistically significant differences in the expression of DAAO. Overall, in controls, the mediodorsal nucleus of the thalamus and CA4 of the hippocampus showed the least expression, while the cortical regions BA46 and 28 showed the highest level of expression (Table 2).
###end p 30
###begin p 31
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
In schizophrenic patients, we noted significant correlations between specific bindings and age (rho = 0.94, P = 0.005) in the left hippocampus along with significant correlations between specific bindings and PMI (rho = 0.90, P = 0.037) in the right hippocampus. Specific binding of DAAO in the hippocampus did not show any significant influences of gender or brain pH.
###end p 31
###begin p 32
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 284 286 284 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 295 296 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 320 321 320 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 329 331 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 340 341 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
From analysis of covariance (ANCOVA, factor diagnosis, covariates age, PMI) intending to adjust the analysis on diagnostic effects for these intervening variables, the noted increase in DAAO-mRNA expression in schizophrenic patients was still significant in both the right (F = 11.1, df = 1, 8, P = 0.013) and the left (F = 9.3, df = 1, 7, P = 0.019) hippocampal CA4 (Fig. 2).
###end p 32
###begin p 33
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Furthermore, schizophrenic patients showed significant correlations between specific bindings and disease duration (rho = 0.83, P = 0.042) as well as duration of medication (rho = 0.83, P = 0.042) in the left CA4. However, correlations of last dose and cumulative dose (last 10 years) with DAAO expression levels were not significant.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2006</xref>
###xml 685 689 685 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2006</xref>
###xml 851 855 851 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2007</xref>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 305 310 <span type="species:ncbi:9606">human</span>
###xml 561 569 <span type="species:ncbi:9606">patients</span>
###xml 778 786 <span type="species:ncbi:9606">patients</span>
###xml 811 816 <span type="species:ncbi:9606">human</span>
###xml 1011 1019 <span type="species:ncbi:9606">patients</span>
To the best of our knowledge, the present post-mortem investigation is the first study showing increased gene expression of DAAO in the left and right hippocampus (CA4) of schizophrenia patients compared to healthy subjects. Concerning mRNA levels, Kapoor et al. (2006) determined the presence of DAAO in human brain tissues from schizophrenic and normal individuals via RT-PCR. They found the relative expression of DAAO-mRNA to be higher in the cerebellum than in the parietal cortex and cerebellar mRNA levels that were significantly higher in schizophrenia patients versus controls. Additionally, they explored DAAO activity in both regions by a colorimetric method (Kapoor et al. 2006) showing that DAAO activity was significantly higher in the cerebellum of schizophrenic patients and undetectable in the human parietal cortex. Bendikov et al. (2007) monitored DAAO protein levels in post-mortem frontal cortex and hippocampus by Western-blot analysis, finding no significant differences in schizophrenia patients. They did note, however, that hippocampal DAAO levels correlated significantly with the duration of disease. This is in line with our findings of a significant correlation between DAAO expression and the duration of disease as well as duration of medication in the left hippocampus. As age, disease duration, and duration of medication are dependent, the respective correlations may be related to each other.
###end p 35
###begin p 36
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2008</xref>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 898 906 <span type="species:ncbi:9606">patients</span>
It must be kept in mind that the present study only measured DAAO expression in a chronic subgroup of schizophrenia patients, as we wanted to assess effects in the most severely affected subgroup in the schizophrenia syndrome. If we had included patients with shorter disease durations, it is possible that our findings would not persist. Madeira et al. (2008) demonstrated an increase in DAAO activity in the parietal cortex of schizophrenic patients. They also found that the group of individuals with a history of antipsychotic drug use showed significantly higher DAAO activity when compared to individuals with no history. The first group included all schizophrenic patients and a subset of patients suffering bipolar disorder. Both psychotic disorders share many features and several authors argue that the illnesses could represent a continuum of symptoms. However, they did not investigate patients of the same diagnostic group without antipsychotics and with antipsychotic treatment, rendering comparisons of treatment effects difficult.
###end p 36
###begin p 37
###xml 22 26 22 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">2006</xref>
###xml 553 555 553 555 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 608 610 608 610 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
While Verrall et al. (2006) discovered a statistically significant increase in the expression of DAAO-mRNA in the cerebellum of schizophrenic patients, but their immunohistochemical studies only showed a trend of the protein level in this direction. In our study, we did not investigate the cerebellum. However, in line with our findings, they reported no differential expression of DAAO in the DLPFC. In this region, Verrall et al. also found a statistically significant increase in the expression of the serine racemase, an enzyme of the synthesis of d-serine, further supporting other disturbances of the d-serine pathway in schizophrenia.
###end p 37
###begin p 38
###xml 117 119 117 119 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2007</xref>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2003</xref>
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2005</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">1996</xref>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2002</xref>
The increased expression of DAAO in both sides of the hippocampus could be responsible for a decrease in hippocampal d-serine (Bendikov et al. 2007; Hashimoto et al. 2003, Hashimoto et al. 2005), leading to a NMDA receptor hypofunction that is thought to occur in schizophrenia (Coyle 1996; Chumakov et al. 2002). By detecting statistically significant increases in DAAO expression values only in the hippocampus and not in any other brain region, alterations of DAAO expression in schizophrenia seem to be region-specific.
###end p 38
###begin p 39
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">2009</xref>
###xml 475 479 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2007</xref>
###xml 616 620 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2001</xref>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
In our study, we investigated Cornu ammonis (CA4) of the left and right hippocampus. Previously, we reported decreased numbers of oligodendrocytes in the left and right hippocampus (CA4) of schizophrenic patients, showing the impact of this region in the pathophysiology of schizophrenia (Schmitt et al. 2009). Among hippocampal subfields, CA4 is the deep polymorph layer of the dentate gyrus and receives collateral mossy fibers from the granulate cells (Amaral and Lavanex 2007). CA4 is among the regions hypothesized to be strongly involved in disturbances of connectivity in schizophrenia (Harrison and Eastwood 2001).
###end p 39
###begin p 40
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2002</xref>
###xml 470 474 470 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2001</xref>
The hippocampus plays an important role in memory consolidation as well as the transfer of memory contents from short-term to long-term memory, and disturbances of verbal memory have been detected in schizophrenia (Heckers and Konradi 2002). Structural magnetic resonance imaging and post-mortem studies in schizophrenia have shown volume loss in the medial temporal region, especially in the hippocampus, as one of the most consistent structural abnormalities (Heckers 2001).
###end p 40
###begin p 41
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">1990</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1993</xref>
###xml 179 183 179 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">1997</xref>
Additionally, post-mortem studies have shown volume loss in hippocampal subregions in schizophrenia, which may be related to positive symptoms (Bogerts et al. 1990, 1993; Bogerts 1997).
###end p 41
###begin p 42
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2008</xref>
###xml 244 246 244 246 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 465 467 465 467 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 512 514 512 514 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 531 533 531 533 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 649 651 649 651 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 854 856 854 856 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 265 268 <span type="species:ncbi:10116">rat</span>
###xml 398 402 <span type="species:ncbi:10090">mice</span>
A new approach regarding pharmacological treatment of schizophrenia is an in vitro and in vivo trial with a selective DAAO inhibitor (Adage et al. 2008). A pharmaceutical product based on selective DAAO inhibitors was not only able to increase d-serine fraction in rat cortex and midbrain, but also had a normalizing effect on phencyclidine (PCP)-induced prepulse inhibition and hyperlocomotion in mice. The mechanism of action of this inhibitor is the increase of d-serine levels by preventing the oxidation of d-serine via DAAO. d-serine is an endogenous full agonist at the glycine site of the NMDA-receptor. By increasing the bioavailability of d-serine, one should consequently achieve enhanced NMDA neurotransmission leading to potential anti-psychotic activities. This new therapeutic approach shows the importance of better insight into the DAAO/d-serine/glycine equilibrium, which should be investigated in large studies to assess and provide proof for new therapy options through modification of the respective equilibrium.
###end p 42
###begin p 43
###xml 115 123 <span type="species:ncbi:9606">patients</span>
In summary, we detected increased gene expression of DAAO in the left and right hippocampus (CA4) of schizophrenia patients compared to a healthy comparison group. These alterations may be related to the pathophysiology of schizophrenia, such as the hypoglutamatergic state with NMDA receptor hypofunction, the GABAergic deficit as well as migrational and myelination disturbances. However, our study also entails some limitations. First, our finding of increased bindings in the left and right hippocampus might not hold up, if a more stringent statistical analysis adjusting of the first kind error probability for the number of investigated regions was applied. Keeping this in mind, the results of this explorative study should be interpreted with caution, until they are confirmed on a larger independent sample. Especially, in the right hippocampus, we investigated only a low number of cases.
###end p 43
###begin p 44
###xml 1028 1030 1028 1030 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
In this post-mortem study, all patients had been treated with typical or atypical neuroleptics over decades, so that one might speculate that antipsychotic treatment itself may have influenced our results. However, as there was no correlation with the cumulative or last dose of antipsychotics in CPE and DAAO expression, we suggest no strong influence of antipsychotic treatment on our results. To gain additional insight animal studies investigating the influence of neuroleptics on DAAO expression are warranted. Furthermore, since many findings in post-mortem tissue are not specific for schizophrenia, psychiatric patients with other diagnoses such as bipolar disorder should be investigated to show disease-specific effects on DAAO expression. Moreover, since we did not investigate protein levels of DAAO isoforms, it is not entirely clear, if changes in the level of the mRNA transcript also reflect changes in protein levels, which again limits our conclusions. Further, post-mortem studies should investigate DAAO and d-serine activity as well as expression of NMDA receptor subunits in the hippocampus to determine whether the change in mRNA results in a functional outcome. Additional investigations are required to clarify the influence of the DAAO gene on the expression of mRNA and protein level, and to identify at-risk polymorphisms within the DAAO and DAOA gene associated with a risk for schizophrenia.
###end p 44
###begin p 45
This study was supported by the European Commission under the Sixth Framework Programme (BrainNet Europe II, LSHM-CT-2004-503039). The paper reflects only the authors' views and the Community is not liable for any use that may be made of it. The authors would like to thank Udo Rueb for Braak staging and Mrs. Waltraud VanSyckel for her valuable assistance with language revision.
###end p 45
###begin p 46
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 46
###begin title 47
References
###end title 47
###begin article-title 48
###xml 70 72 70 72 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties
###end article-title 48
###begin article-title 49
Hippocampal neuroanatomy
###end article-title 49
###begin article-title 50
###xml 36 38 36 38 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia
###end article-title 50
###begin article-title 51
The temporolymbic system theory of positive schizophrenic symptoms
###end article-title 51
###begin article-title 52
Post-mortem volume measurements of limbic system and basal ganglia structures in chronic chizophrenics. Initial results from a new brain collection
###end article-title 52
###begin article-title 53
Hippocampua-amygdala volumes and psychopathology in chronic schizophrenia
###end article-title 53
###begin article-title 54
Neuropathological staging of Alzheimer-related changes
###end article-title 54
###begin article-title 55
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
###end article-title 55
###begin article-title 56
###xml 83 85 83 85 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 51 56 <span type="species:ncbi:9606">human</span>
Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid ocidase in schizophrenia
###end article-title 56
###begin article-title 57
###xml 0 2 0 2 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
d-amino acid oxidase (DAO) genotype and mood symptomatology in schizophrenia
###end article-title 57
###begin article-title 58
The glutamatergic dysfunction hypothesis for schizophrenia
###end article-title 58
###begin article-title 59
Linkage studies of bipolar disorder in the region of the Darier's disease gene on chromosome 12q23-24.1
###end article-title 59
###begin article-title 60
G72/G30 in Schizophrenia and bipolar disorder: review and meta-analysis
###end article-title 60
###begin article-title 61
The G72/G30 gene complex and cognitive abnormalities in schizophrenia
###end article-title 61
###begin article-title 62
The neuropathology of schizophrenia: a critical review of the data and their interpretation
###end article-title 62
###begin article-title 63
Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia
###end article-title 63
###begin article-title 64
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
###end article-title 64
###begin article-title 65
###xml 26 28 26 28 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 103 105 103 105 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia
###end article-title 65
###begin article-title 66
###xml 8 10 8 10 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients
###end article-title 66
###begin article-title 67
Neuroimaging studies of the hippocampus in schizophrenia
###end article-title 67
###begin article-title 68
Hippocampal neurons in schizophrenia
###end article-title 68
###begin article-title 69
###xml 0 2 0 2 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 75 78 <span type="species:ncbi:10116">rat</span>
d-Amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes
###end article-title 69
###begin article-title 70
Die statistische Kontrolle moglicher Medikamenteneinflusse in experimentalpsychologischen Schizophreniestudien: ein Vorschlag zur Berechnung von Chlorpromazinaquivalenten
###end article-title 70
###begin article-title 71
Specificity of developmental precursors to schizophrenia and affective disorders
###end article-title 71
###begin article-title 72
###xml 111 113 111 113 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1)
###end article-title 72
###begin article-title 73
A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22
###end article-title 73
###begin article-title 74
Schizophrenia as a disorder of neurodevelopment
###end article-title 74
###begin article-title 75
G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies
###end article-title 75
###begin article-title 76
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAAO</italic>
Association of DAAO with schizophrenia in the Chinese population
###end article-title 76
###begin article-title 77
###xml 16 18 16 18 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia
###end article-title 77
###begin article-title 78
###xml 26 28 26 28 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 20 25 <span type="species:ncbi:9606">human</span>
Characterization of human d-amino acid oxidase
###end article-title 78
###begin article-title 79
###xml 41 43 41 43 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
Engineering the substrate specificity of d-amino-acid oxidase
###end article-title 79
###begin article-title 80
###xml 0 2 0 2 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
d-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release
###end article-title 80
###begin article-title 81
Stereologic investigation of the posterior part of the hippocampus in schizophrenia
###end article-title 81
###begin article-title 82
###xml 23 25 23 25 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
Examination of G72 and d-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder
###end article-title 82
###begin article-title 83
Genetic associations with schizophrenia: meta-analyses of 12 candidate genes
###end article-title 83
###begin article-title 84
###xml 0 2 0 2 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
d-amino acid oxidase and serine racemase expression in the dorso-lateral pre-frontal cortex in schizophrenia
###end article-title 84
###begin article-title 85
Implications of normal brain development for the pathogenesis of schizophrenia
###end article-title 85
###begin article-title 86
###xml 45 47 45 47 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 85 87 85 87 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
Serine racemase: a glial enzyme synthesizing d-serine to regulate glutamate-N-methyl-d-aspartate neurotransmission
###end article-title 86
###begin article-title 87
Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia
###end article-title 87
###begin article-title 88
###xml 0 2 0 2 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d-</sc>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
d-serine enhances impaired long-term potentiation in CA1 subfield of hippocampal slices from aged senescence-accelerated mouse prone/8
###end article-title 88
###begin article-title 89
###xml 78 81 <span type="species:ncbi:10116">rat</span>
Antidepressants differentially affect expression of complexin I and II RNA in rat hippocampus
###end article-title 89

